Log In
Print
BCIQ
Print
Print this Print this
 

bedaquiline (Sirturo) (TMC207) (formerly R207910)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionDiarylquinoline (DARQ) antibiotic
Molecular Target Mycobacterial F1F0-ATP synthase
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationTuberculosis
Indication DetailsTreat multidrug-resistant tuberculosis (MDR-TB); Treat tuberculosis (TB) infection
Regulatory Designation

U.S. - Accelerated Approval (Treat multidrug-resistant tuberculosis (MDR-TB));
EU - Orphan Drug (Treat multidrug-resistant tuberculosis (MDR-TB))

Partner

Global Alliance for TB Drug Development; Pharmstandard JSC


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today